Clinical Trials Logo

Hypotension clinical trials

View clinical trials related to Hypotension.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05158153 Terminated - Acute Kidney Injury Clinical Trials

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis

ORKID
Start date: October 18, 2021
Phase: Phase 4
Study type: Interventional

There are currently no therapies to improve the chances of recovering enough kidney function to come off of dialysis after severe acute kidney injury. It is not known if current routine outpatient dialysis treatments are optimized to maximize the chances of recovery. The purpose of this pilot study is to see if we can feasibly and safely provide several changes to the way that dialysis is provided in outpatient dialysis centers which may improve the chances of recovery.

NCT ID: NCT05105477 Terminated - Clinical trials for Moderate to High-risk Noncardiac Surgery

Hypotension Prediction Index (HPI) SMART-BP Trial

Start date: November 17, 2021
Phase: N/A
Study type: Interventional

A multicenter, randomized comparison of intraoperative hemodynamic management with or without a protocolized strategy utilizing Hypotension Prediction Index (HPI) software guidance during moderate-to-high-risk noncardiac surgery.

NCT ID: NCT05051150 Terminated - Cesarean Section Clinical Trials

Epinephrine Infusion for Prophylaxis Against Maternal Hypotension During Caesarean Section

Start date: September 15, 2021
Phase: Phase 4
Study type: Interventional

Maternal hypotension after spinal block is a common complication after subarachnoid block in this population. The incidence of maternal hypotension is nearly 60% when prophylactic vasopressors are not used. Therefore, it is highly recommended to use vasopressors, preferably as continuous infusion, for prophylaxis rather than delaying their use until hypotension occurs. Phenylephrine (PE) is the recommended drug for prophylaxis against hypotension during cesarean delivery; however, the use of PE is commonly associated with decreased heart rate and probably cardiac output because PE is a pure alpha adrenoreceptor agonist . Introduction of NE in obstetric practice had shown favorable maternal and neonatal outcomes and was associated with higher heart rate and cardiac output compared to PE. However, there is still some mothers who develop bradycardia and diminished cardiac output with the use of NE. The most desired scenario during hemodynamic management of mothers during cesarean delivery would achieve the least possible incidences of maternal hypotension, bradycardia and reactive hypertension. Therefore, it is warranted to reach a vasopressor regimen with the most stable hemodynamic profile. In the last year, epinephrine was reported for the first time in obstetric practice with acceptable safety on the mother and the fetus. However, there is still lack of data about the most appropriate dose for infusion during cesarean delivery. In this study, we aim to compare three prophylactic infusion rates for epinephrine during cesarean delivery.

NCT ID: NCT04538079 Terminated - Clinical trials for Hemodynamic Instability

Non-invasive Objective Assessment of Hemodynamics in Preterm Neonates

NOAH
Start date: November 9, 2019
Phase:
Study type: Observational

Study type: Prospective Observational trial Study design: Longitudinal Population: Preterm newborns <32 weeks gestational age Hypothesis: The inclusion of non-invasive physiological measures of cardiac output, peripheral perfusion and brain oxygenation (NIRS) for preterm neonates is feasible and reveals additional information on the hemodynamic status compared to blood pressure alone. These measurements can improve the ability to rapidly identify those infants who might benefit from intervention and are correlated with short term clinical outcomes.

NCT ID: NCT04220281 Terminated - Clinical trials for Hypotensive Anesthesia

Comparison Between Two Drugs (Propofol and Nitroglycerin as a Hypotensive Agents During Endoscopic Sinus Surgery

prop
Start date: December 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Background and Objectives: FESS is a common minimally invasive surgery that requires a clear field to be performed well. Hypotensive anesthesia is one of the most common maneuvers performed to help in keeping the field clear. An ideal drug for hypotensive anesthesia should be cheap and familial to the anesthesiologist. So being familial with propofol and by using its cardio-depressant action the idea of the research was developed and comparing it with nitroglycerin (a hypotensive agent in our protocol). Methods: The patients agreed to participate in the research were classified into two groups for comparison. Propofol group; received propofol infusion all over the procedure, and nitroglycerin group; received nitroglycerin infusion all over the procedure. Duration of surgery, visibility of surgical field and amount of blood loss were recorded. Pulse/min and MAP were recorded at baseline and every 5 min. Results: The mean duration of surgery was longer in the NTG to propofol group. There was high statistical significance in the average blood loss in the propofol group compared to NTG group. The visibility of the operative field also was significant in the propofol group as compared to NTG group. The mean heart rate in the NTG group is higher than the mean heart rate in the propofol group. The MAP in both groups is within a close range. Conclusion: Propofol and NTG can produce a safe and effective controlled hypotension during FESS. Whereas, propofol has; a better surgical field visibility, less surgical bleeding and less tachycardia during FESS.

NCT ID: NCT04095793 Terminated - Clinical trials for Symptomatic Neurogenic Orthostatic Hypotension

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

OAK
Start date: September 19, 2019
Phase: Phase 3
Study type: Interventional

A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.

NCT ID: NCT03829657 Terminated - Clinical trials for Parkinson's Disease (PD)

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

REDWOOD
Start date: February 22, 2019
Phase: Phase 3
Study type: Interventional

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

NCT ID: NCT03407287 Terminated - Atrial Fibrillation Clinical Trials

Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status

PIVA
Start date: January 8, 2018
Phase:
Study type: Observational

The aim of this study is to determine the effects of fluid alternations, hemodynamic changes, mechanical ventilation, pharmacologic agents, positional changes, and comorbidities on the Peripheral Intravenous waveform Analysis (PIVA) signal.

NCT ID: NCT03313375 Terminated - Clinical trials for Postexercise Hypotension

Continuous vs Aerobic Postexercise Hypotension

CAPER
Start date: October 5, 2017
Phase: N/A
Study type: Interventional

This study examines the effect of obesity and gender on postexercise hypotension with three different randomized exercise protocols or varying intensity. Subjects will be separated into obese and non-obese groups and then further by gender. From there, they will be put through a control, continuous exercise bout, and aerobic interval bout of exercise in a randomized order over three visits. Post exercise blood pressure, as well as other non-invasive cardiac measures will be taken over a 4 hour period.

NCT ID: NCT03214809 Terminated - Dyspnea Clinical Trials

The Use of a Point-of-care Thoracic Ultrasound Protocol for Hospital Medical Emergency Teams

METUS
Start date: January 18, 2019
Phase: N/A
Study type: Interventional

Study to assess the possible effects of the use of a point-of-care thoracic ultrasound protocol for hospital medical emergency teams (MET)